Our experience in the treatment of Malignant Fibrous Hystiocytoma of the larynx: clinical diagnosis, therapeutic approach and review of literature

Domenico Testa; Sergio Motta; Giuseppina Marcuccio; Marianna Paccone; Aldo Rocca; Gennaro Ilardi; Domenico Tafuri; Massimo Mesolella; Gaetano Motta

doi:10.1515/med-2016-0040

Enjoy 40% off

academic books on De Gruyter Brill *

Article Open Access

Our experience in the treatment of Malignant Fibrous Hystiocytoma of the larynx: clinical diagnosis, therapeutic approach and review of literature

Domenico Testa , Sergio Motta , Giuseppina Marcuccio , Marianna Paccone , Aldo Rocca , Gennaro Ilardi , Domenico Tafuri , Massimo Mesolella and Gaetano Motta

Published/Copyright: June 23, 2016

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Open Medicine Volume 11 Issue 1

Abstract

Hereditary spherocytosis (HS) and Chronic myelocytic leukemia (CML) are both life threatening hemotologic diseases. They are rarely seen to occur simultaneously in one individual patient. Here we demonstrate a case of HS associated with CML in this study. The patient is a young female, diagnosed with HS in 2005, and was given partial embolization of the splenic artery. She got significant remission after the procedure. In 2008, she was found abnormal in blood routine test, after bone marrow routine, chromosome and fusion gene tests, she was diagnosed with CML (chronic phase). She did not receive regular treatment until 3 months prior, and is currently being treated with Dasatimib. She achieved hematological remission, but had no significant improvement in chromosome and fusion gene figures. Due to her severe condition of hemolysis, a splenectomy or an allogeneic hematopoietic stem cell transplantation is considered.

Keywords: Malignant Fibrous Hystiocytoma (MFH); CO2 Laser Cordectomy; Vocal Cord Cancer; Glottic sarcoma

1 Introduction

Malignant Fibrous Histiocytoma, MFH, is a primitive, often pleomorphic, soft tissue sarcoma characterized by fibrous tissue with fibroblasts, histiocytes and myofibro-blasts [1-5]. It was first described by O’Brein and Stout in 1964, as a ‘fibrous histiocytoma or fibrous xanthoma.’ It is assumed that in fibrous histiocytoma, cells behave as phagocytes but also form connective tissue fibers; whereas in pure histiocytoma no fibers are formed [5]. In 1983, Enzinger and Weiss, described storiform-pleomorphic, myxoid, giant cells, inflammatory and angiomatoid variants [6,7].

Storiform-pleomorphic phenotype is the most frequent; few cases of low differentiation MFH can be distinguished in high-grade pleomorphic sarcoma, pleomorphic sarcoma with giant cells and inflammatory pleomorphic sarcoma [8].

MFH is the most common subtype of soft tissue sarcoma in adults, described in bone, viscera and skin [9-12], it remains a rare malignancy in the head and neck region (3-13% of all malignant lesions), and it occurs even more rarely in the larynx, 10-15% of these cases [13-15].

As all sarcomas, the development of MFH is unrelated to smoking and alcohol consumption. Some sarcomas are related to genetic syndromes such as Li Fraumeni, neuro-fibromatosis, or rarely Cutis Laxa [4,16].

MFH can be correlated to hereditary mutations of oncosuppressor genes or environmental mutagens exposure as commonly reported in bowel tumors [17,18]; it is one of the most common radiation-associated sarcomas, accounting for almost 50% of all cases occurring in both bone and soft tissue [19,20].

43 cases of MFH of the larynx have been described in literature since 1972. Rolander et al. studied a review of case reports of MHF: 8 cases in supraglottic region (2 of these of epiglottis, 4 of aryepiglottic fold, 1 of Morgagni ventricle, 1 not specified); 19 glottis region (17 of vocal cords, 1 of anterior commissura, 1 not specified); 8 in subglottis region; 6 in not specified region; 1 in hemilarynx and 1 case of transglottic cancer (vocal cord and Morgagni ventricle) (Table 1).

Table 1

Clinical case review of MFH of the larynx.

Author	Year	Ages/Sex	Location	Treatment/Recurrence
Rolander et al	1972	56/M	Epiglottis	Supraglottic laryngectomy, neck dissection/NER
Coyas et al	1974	67/M	Vocal Cord	Tumor excision/Recurrence
Canalis et al	1975	53/M	Vocal Cord	Piecemeal excision/Recurrence
Ribari et al	1975	35/M	Subglottis	Tumor excision/Radiotherapy
Ferlito	1976	46/M	Larynx	Total Laryngectomy + Radiotherapy/Recurrence
Johnson and Poushtes	1977	67/F	Subglottis	Tumor excision/Recurrence
Ferlito	1978	58/M	Subglottis	Tumor excision/Recurrence
Ferlito	1979	68/M	Aryepiglottic fold	Total Laryngectomy /NER
Keenan et al	1979	22/F	Subglottis	Tumor endoscopic excision/Recurrence
Setzen et al	1979	ND	ND	ND
Setzen et al	1979	ND	ND	ND
Ogura et al	1980	22/F	Subglottis	Segmental cricotracheal resection/NER
Ogura et al	1980	28/M	Subglottis	Partial cricotracheal resection/NER
Neblett and Coller	1891	22/F	Morgagni Ventricle	Partial Laryngectomy/NER
Bremer et al	1982	45/M	ND	ND
Bremer et al	1982	30/M	ND	ND
Yokoi et al	1982	64/F	Vocal cord	Tumor excision /NER
Ferlito et al	1983	67/M	Vocal cord	Total Laryngectomy + Radiotherapy/ Recurrence
Ferlito et al	1983	51/M	Vocal cord	Total Laryngectomy /NER
Ferlito et al	1983	63/M	Emilarynx	Laryngectomy and pharyngo esophagectomy /NER
Ferlito et al	1983	8/F	Subglottis	ND
Radamass	1984	45/M	Vocal Cord	Total Laryngectomy/NER
Lobe and Katewkamp	1984	67/M	ND	Radiotherapy/NER
Volmer	1985	70/M	Vocal Cord	Tumor excision + Radiotherapy / NER
Volmer	1985	38/M	Vocal Cord	Tumor excision / NER
Godoy et al	1986	26/F	Subglottis	Total Laryngectomy /NER
Barnes e Kanbour	1988	68/M	Vocal cord	Total Laryngectomy /NER
Masuda et al	1989	80/M	Vocal cord	Tumor excision / NER
Saha et al	1989	58/M	Epiglottide	Tracheotomy and Radiotherapy/ Recurrence
Majumder et al	1989	45/M	Aryepiglottic fold Supraglottis	Total Laryngectomy + Radiotherapy/NER
Jordan and Soames	1989	54/M	Vocal cord	Tumor excision / Recurrence
Colev et al	1989	57/M	Aryepiglottic fold	ND
Colev et al	1989	64/M	Vocal cord	ND
Colev et al	1989	75/M	Vocal cord	ND
Rosa et al	1990	78/M	Vocal cord	Chordectomy/ Recurrence
Bernaldez et al	1991	54/M	Vocal cord and Morgagni ventricle	Total Laryngectomy /NER
Weber et al	1992	ND/M	Vocal cord	ND
Weber et al	1992	ND/M	Plica ariepiglottica	ND
Harmoir et al	1993	24/F	ND	ND
Kuwabara et al	1993	46/M	Vocal cord	CO2 laser Tumor excision /NER
Pastore et al	2001	32/M	Laryngeal Vestibule	Lateral Pharyngothiroidotomy, thyroid-hyoidpessia+radiotherapy/NER
Ortizbish et al	2004	54/M	Vocal cord	Chordectomy with laryngofissure/ Recurrence
Ortizbish et al	2004	67/M	Anterior Commissura	Tumor excision /NER
Anghelina et al	2009	59/M	Vocal cord	Tumor excision /NER
Testa et al	2015	84/M	Cord-commissural	CO2 laser Tumor excision /NER

Surgery with en-block resection of tumor is the first treatment choice: 60% of patients may survive over 5 years, and 40% over 10 years [14,15,19]. Radiotherapy is given to patients with risk of recurrence, in non-surgical patients or in cases with metastasis [20-24].

Adjuvant or neoadjuvant chemotherapy is suggested when patients have high risk of recurrence [25-27]. The prognosis is related to tumor differentiation, vascular invasion, size (over 5 cm), metastasis [25-28].

Endothelial Progenitor Cells (EPCs) a promising target of cell based therapy, just used in several benign and malignant diseases, should be a possible innovative non surgical approach [29-37].

We present one case of a cord-commissural MFH of larynx, the first treated in microlaryncoscopy with CO² laser.

2 Case report

C.L., 84 year-old male, smoker for 50 years, was admitted to the Department of Otorhinolaryngology of the Second University of Naples in March 2009. He had had hoarseness for 8 months and there had been familial cases of tumors, such as lung adenocarcinoma. During fiberoptic laryngoscopy, we discovered a red-violaceous nodular lesion of the left vocal cord and of the anterior commissure, with hypomobility of the left vocal chord (Figure 1); there was no palpable cervical lymphadenopathy. CT-scan of the neck and thorax was performed, showing a laryn-geal mass infiltrating the left vocal cord and the anterior commissural; no cervical lymph nodes and no metastases were found. Transoral endoscopic cordectomy of the left vocal cord and of anterior commissural was performed in microlaryngoscopy with CO₂ (IVd) (Figure 2).

Figure 1

Fibrolaryngoscopy: red-violaceous nodular lesion of the left vocal cord and anterior commissure.

Figure 2

Microlaryngoscopic vision of the operative field after laser cordectomy.

The surgical specimen was sent for histological examination.

At microscopic evaluation, a lesion, was observed, mostly formed of spindle-shaped malignant cells arranged in a fascicular/storiform pattern of growth, with several highly pleomorphic elements, in the corion. Moreover, a significant number of osteoclast-like giant-cells, with hypercrhomatic and slightly atypical nuclei, were found. A focal collagen deposition, consisting of bundles of fibrillar eosinophilic material, was associated.

At the immunohistochemical exam, the lesion showed a strong and diffuse positivity to vimentin and mild reactivity for CD68, more prominently in the giant cells counterpart. Finally, a diagnosis of malignant fibrous histiocytoma (MFH) was made (Figure 3).

Figure 3

Microscopic evaluation showed a lesion mostly formed of spindle-shaped malignant cells arranged in a fascicular/stori-form pattern of growth, with several highly pleomorphic elements, was observed in the corion. (green arrow). Moreover, a significant number of osteoclast-like giant-cells, with hyperchromatic and slightly atypical nuclei, were found (blue arrows). A focal collagen deposition, consisting of bundles of fibrillar eosinophilic material, was associated (red arrows). At the immunohistochemical exam, the lesion showed a strong and diffuse positivity to vimentin and a mild reactivity to CD68, more prominently in the giant cells counterpart. Finally, a diagnosis of malignant fibrous histiocytoma (MFH) was made.

At follow-up, laryngoscopy was performed every month for the first year after surgery and then every two months during the last three years. At the last follow-up examination, five year after surgery, the patient was asymptomatic and there was no recurrence of lesions.

Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.

Informed consent: Informed consent has been obtained from all individuals included in this study.

3 Discussion

In 1964, O’ Brein and Stout first defined MHF, in order to describe a histiocytic-like tumor with predominant fibroblasts [5]. MFH of the larynx is a rare disease, comprising approximately less than 2% of all head and neck tumors [19]. It is divided histologically into five variants: storiform-pleomorphic, myxoid, giant cells, inflammatory and angiomatous. Immunohistochemistry is needed to differentiate MFH from other malignant tumors such as sarcomatoid carcinoma (AE1/AE3-negativity), malignant shwannoma and melanoma (S100-negativity), angiosarcoma (CD3- negativity), rhabdomyosarcoma (myoglobin-negativity) [7].

The neoplastic cells of MFH are positive to vimentin and CD68 (histiocytic marker) and focally positive to S100 (neuroectodermic marker) and to smooth muscle actin (SMA) [7]. Age related incidence ranges from 4 to 84 (our patient) years; only one case occurring in a child (8 year-old female, 2,3% of all cases) [9], 8 cases (4 female and 4 male, 18,2% of all cases) [9] all between 20-30 years old. MFH is more common in male patients than in female (M:F, 4:1) [20]. Radiotherapy is given when patients have high risk of recurrence, in non-operated patients or in cases with metastasis; adjuvant or neoadjuvant chemotherapy is suggested when patients have high risk of recurrence [20-24]. The prognosis is related to tumor differentiation, vascular invasion, size (over 5 cm), resection margins, metastasis: 60% of the patients may survive over 5 years, and 40% of the patients may survive over 10 years [25-27].

Of the 43 cases of MFH of the larynx described since 1972 (Rolander et al.: 8 cases occurred in the supraglottic region (2 of these of epiglottis, 4 of aryepiglottic fold, 1 of Morgagni ventricle, 1 not specified); 19 in glottis region (17 of vocal cords, 1 of anterior commissura, 1 not specified); 8 in the subglottis region; 6 in unspecified regions; 1 in hemilarynx and 1 case of transglottic cancer (vocal cord and Morgagni ventricle) (Table 1). We have indicated treatments, recurrences and follow-ups in tab.1 [20]. Surgical intervention is the first choice of treatment and the majority of authors used demolitive surgical techniques: total, partial or supraglottic laryngectomy; traditional cordectomy, tumor excision, partial cricotracheal resection; in 1994 Kuwabara et al., described a glottic MFH (vocal cord) treated with CO² laser [22]. In our case CO² laser treatment wasn’t associated to vocal cord lesion or paralysis [38].

In literature 8 Italian cases of MFH occurring in Italy were described from 1976 (Ferlito et al.) [23] to 2001 (Pastore et al.) [24], 7 male and 1 female, mean age 49.7 : 2 glottic cases, 2 supraglottic, 2 ipoglottic, 1 transglottic and 1 undetermined (Table 2) [20-22].

Table 2

Italian cases of MFH of the larynx.

Author	Year	Ages/Sex	Location	Treatment/Recurrence	Subsequent Tratment
Ferlito	1976	46/M	NS	Total Laryngectomy/NER	Hypopharyngectomy+CT
Ferlito	1978	58/M	Hypoglottis	Tumor excision/Recurrence	Emilaringectomia e poi Laringectomia Totale
Ferlito	1979	68/M	Aryepiglottic fold	Total Laryngectomy/NER
Ferlito et al	1983	67/M	Vocal Cord	Total Laryngectomy + RT/Ricurrence	ND
Ferlito et al	1983	51/M	Vocal Cord	Total Laryngectomy/NER
Ferlito et al	1983	63/M	Emilarynx	Laryngectomy and pharyngo esophagectomy /NER	-
Ferlito et al	1983	8/F	Subglottis	ND	ND
Pastore et al	2001	32/M	Laryngeal Vestibule	Lateral Pharyngothiroidotomy, thyroid-hyoidpessia+radiotherapy/NER	-
Testa et al	2014	84/M	Cord-commissural	CO2 Laser/NER

4 Conclusions

Our case represents the second case in literature of commissural MFH. Ortiz Bish et al. in 2004 described the first in 2004 [39], a 64 year old male who underwent traditional tumor excision and 6 months after surgery he did not present any recurrences [25-27]. We performed CO²_-laser tumor excision, the first time used in Italy for MFH of larynx.

Five years after surgery, without any adjuvant treatment, did not present any recurrence.

Malignant fibrous histiocytomas are a very rare mesenchymal neoplasm of the larynx. At present, no guidelines for laryngeal MFH exist because of lack of evidence-based data, the treatment of choice is surgical, in some cases associated with radiotherapy and chemotherapy. An innovative approach should be considered a cell based therapy using Endothelial Progenitor Cells (EPCs) [29-37]. EPCs pathogenic mechanisms involving in vascular and non vascular diseases includes several biomarkers and Ca²⁺ toolkit. [40-49].

We found 43 cases of MFH of the larynx, in literature the presented case is the second cord-commissural case described and the only commissural one treated with CO² laser surgery.

Conflict of interest statement

Authors state no conflict of interest.

References

[1] Kaufmann SL, Stout AP. Histiocytic tumors (fibrous xanthoma and histiocytoma) in children. Cancer 1961;14:469-48210.1002/1097-0142(199005/06)14:3<469::AID-CNCR2820140304>3.0.CO;2-QSearch in Google Scholar

[2] Ozello L, Stout AP, Murray MR. Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer 1963; 16:331-34410.1002/1097-0142(196303)16:3<331::AID-CNCR2820160307>3.0.CO;2-FSearch in Google Scholar

[3] Testa D, Galli V, De Rosa G, Iovine R, Staibano S, Somma P et al. Clinical and prognostic aspects of laryngeal clear cell carcinoma. Journal of Laryngology and Otology 2005 Dec;119(12):991-99410.1258/002221505775010715Search in Google Scholar

[4] MCMains KC, Gourin CG. Pathology: sarcomas of the head and neck. http://emedicine.medscape.com/article/87128, accessed 02/0172010Search in Google Scholar

[5] O’Brein JE, Stout AP. Malignant fibrous xanthomas. Cancer 1964; 17:1445-145510.1002/1097-0142(196411)17:11<1445::AID-CNCR2820171112>3.0.CO;2-GSearch in Google Scholar

[6] Arnold HL Jr and Tilden IL. Hystiiocytoma cutis; variant of xanthoma; histologic and chemical studies of 27 lesions in 23 cases. Arch Dermat Syph 1943; 47: 498-51610.1001/archderm.1943.01500220036005Search in Google Scholar

[7] Enzinger FM, Weiss SW. Malingant fibro-histiocytic tumors, in Endinger FM, Weuss SW (eds). (1983) Soft Tissue Tumors. St Louis, CV Mosby Co, pp 166-198Search in Google Scholar

[8] Fletcher CDM, Unni KK, Mertens F. Pathology and genetics of tumors of soft tissue and bone. Lyon: IARC Press; 2002Search in Google Scholar

[9] Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 1978; 41:2250-226610.1002/1097-0142(197806)41:6<2250::AID-CNCR2820410626>3.0.CO;2-WSearch in Google Scholar

[10] Huvos AG, Heilweil M, Bretsky SS. the pathology of malignant fibrous histiocytoma of bone: a study of 130 patients. Am J Surg Pathol 1985; 9:853-87110.1097/00000478-198512000-00002Search in Google Scholar

[11] Yousem SA, Hochholzer L. Malignant fibrous histiocytoma of the lung. Cancer 1987; 60:2532-254110.1002/1097-0142(19871115)60:10<2532::AID-CNCR2820601031>3.0.CO;2-5Search in Google Scholar

[12] Enzinger FM, Weiss SW. Malignant fibro-histiocytic tumors, in Enzinger FM, Weiss SW (eds) (1983) Soft Tissue Tumors. St Louis, CV Mosby Co, pp 166-198Search in Google Scholar

[13] Restrepo JP, Handler SD, Saull SC. Malignant fibrous histiocytoma. Otolaryngol Head Neck Surg 1987; 96:362-36510.1177/019459988709600409Search in Google Scholar

[14] Testa D, Motta G, Galli V, Iovine R, Guerra G, Marenzi G et al. Outcome assessment in patients with chronic obstructive rhinitis CO2 laser treated. Acta Otorhinolaryngol 2006; 26(1):32-37Search in Google Scholar

[15] Motta G, Esposito E, Motta S, Tartaro GP, Testa D. CO2 laser surgery in the treatment of glottic cancer. Head & Neck 2005; 27 (7), 566-57410.1002/hed.20135Search in Google Scholar

[16] Paladini D, Di Spiezio Sardo A, Mandato VD, Guerra G, Bifulco G, Mauriello S et al. Association of Cutis Laxa and genitale prolapse: a case report International Urogynecology Journal 2007;18(11):1367-137010.1007/s00192-007-0362-4Search in Google Scholar

[17] Truta B, Allen BA, Conrad PG, Weinberg V, Miller GA, Pomponio R et al. A comparison of the phenotype and genotype in adenomatous polyposis patients with and without a family history. Fam Cancer. 2005; 4(2):127-13310.1007/s10689-004-5814-0Search in Google Scholar

[18] Thirlwell C, Howarth KM, Segditsas S, Guerra G, Thomas HJ, Phillips RK et al. Investigation of pathogenic mechanisms in multiple colorectal adenoma patients without germline APC or MYH/MUTYH mutations. Br J Cancer 2007; 96(11):1729-173410.1038/sj.bjc.6603789Search in Google Scholar

[19] Sturgis EM, Potter BO. Sarcomas of the head and neck region. Curr Opin Oncol 2003; 15:239-25210.1097/00001622-200305000-00011Search in Google Scholar

[20] Ko JY, Chen CL, Lui LT, Hsu MM. Radiation-induced malignant fibrous histiocytoma in patients with nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 1996; 122:535-53810.1001/archotol.1996.01890170067013Search in Google Scholar

[21] Abramowsky CR, Witt WJ. Sarcoma of the larynx in a newborn. Cancer 1983; 51:1726-173010.1002/1097-0142(19830501)51:9<1726::AID-CNCR2820510928>3.0.CO;2-WSearch in Google Scholar

[22] Kuwabara H, Saito K, Shibanushi, Kuwahara T. Malignant Fibrous histiocytoma of the larynx. Eur Arch Otorhinolaryngol 1994; 251: 178-18210.1007/BF00181832Search in Google Scholar

[23] Ferlito A. Simultaneous malignant pleomorphic fibrous histiocytoma and squamous cell carcinoma “in situ” of the larynx. Acta Otorhinolaryngol Belg 1976; 30:390-397Search in Google Scholar

[24] Pastore A, Grande E, Targa L, Marchese Ragona R. Malignant Fibrous Histiocytoma of the Larynx. Case Report and Review of the literature. Acta otorhinolaryngol Ita 2001; 21:361-364Search in Google Scholar

[25] Bernaldez R, Nistal M, Kaiser C, Gavilan J. Malignant fibrous histiocytoma of the larynx. J Laryngol Otol 1991; 105(2):130-13310.1017/S0022215100115154Search in Google Scholar

[26] Godoy J, Jacobs JR, Crissman J. Malignant fibrous histiocytoma of the larynx. J Surg Oncol 1986; 31(1):62-6510.1002/jso.2930310115Search in Google Scholar

[27] Nascimento AF, Raut CP. Diagnosis and Management of Pleomorphic Sarcomas (so-called “MFH”) in Adults. J Surg Oncol 2008; 97:330-33910.1002/jso.20972Search in Google Scholar

[28] Mairal A, Terrier P, Chibon F. Loss of chromosome 13 is the most frequent genomic imbalance in malignant fibrous histio-cytomas. A comparative genomic hybridization analysis of a series of 30 cases. Cancer Genet Cytogenet 1999; 111:134-13810.1016/S0165-4608(98)00227-1Search in Google Scholar

[29] Moccia F, Dragoni S, Lodola F, Bonetti E, Bottino C, Guerra G et al. Store-dependent Ca²⁺ entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularisation. Curr Med Chem 2012 Dec 1;19(34):5802-581810.2174/092986712804143240Search in Google Scholar PubMed

[30] Moccia F, Lodola F, Dragoni S, Bonetti E, Bottino C, Guerra G et al. Ca²⁺ signalling in endothelial progenitor cells: a novel means to improve cell-based therapy and impair tumour vascularisation. Curr Vasc Pharmacol. 2014 Jan;12(1):87-10510.2174/157016111201140327162858Search in Google Scholar PubMed

[31] Moccia F, Dragoni S, Cinelli M, Montagnani S, Amato B, Rosti V et al. How to utilize Ca²⁺ signals to rejuvenate the repairative phenotype of senescent endothelial progenitor cells in elderly patients affected by cardiovascular diseases: a useful therapeutic support of surgical approach? BMC Surg 2013 Oct 8;13(Suppl 2):S4610.1186/1471-2482-13-S2-S46Search in Google Scholar PubMed PubMed Central

[32] Dragoni S, Laforenza U, Bonetti E, Reforgiato M, Poletto V, Lodola F et al. Enhanced Expression of Stim, Orai, and TRPC Transcripts and Proteins in Endothelial Progenitor Cells Isolated from Patients with Primary Myelofibrosis. PLoS One 2014 Mar 6;9(3):e9109910.1371/journal.pone.0091099Search in Google Scholar PubMed PubMed Central

[33] Lodola F, Laforenza U, Bonetti E, Lim D, Dragoni S, Bottino C et al. Store-operated ca(2+) entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients. PLoS One 2012 7(9):e4254110.1371/journal.pone.0042541Search in Google Scholar PubMed PubMed Central

[34] Dragoni S, Turin I, Laforenza U, Potenza DM, Bottino C, Glasnov TN et al. Store-operated ca(2+) entry does not control proliferation in primary cultures of human metastatic renal cellular carcinoma. Biomed Res Int. 2014;2014:73949410.1155/2014/739494Search in Google Scholar PubMed PubMed Central

[35] Moccia F, Zuccolo E, Poletto V, Cinelli M, Bonetti E, Guerra G et al. Endothelial progenitor cells support tumour growth and metastatisation: implications for the resistance to anti-angiogenic therapy. Tumour Biol. 2015 Aug;36(9):6603-661410.1007/s13277-015-3823-2Search in Google Scholar PubMed

[36] Dragoni S, Reforgiato M, Zuccolo E, Poletto V, Lodola F, Ruffinatti FA et al. Dysregulation of VEGF-induced proangiogenic Ca²⁺ oscillations in primary myelofibrosis-derived endothelial colony forming cells. Exp Hematol. 2015 Dec;43(12):1019-1030.e310.1016/j.exphem.2015.09.002Search in Google Scholar PubMed

[37] Zuccolo E, Bottino C, Diofano F, Poletto V, Codazzi AC, Mannarino S et al. Constitutive store-operated C^a2+ entry leads to enhanced nitric oxide production and proliferation in infantile hemangioma-derived endothelial colony forming cells. Stem Cells Dev. 2015 Dec 9. [Epub ahead of print]10.1089/scd.2015.0240Search in Google Scholar PubMed

[38] Testa D, Guerra G, Landolfo PG, Nunziata M, Conzo G, Mesolella M et al. Current therapeutic prospectives in the functional rehabilitation of vocal fold paralysis after thyroidectomy: CO2 laser aritenoidectomy. Int J Surg. 2014;12 Suppl 1:S48-5110.1016/j.ijsu.2014.05.055Search in Google Scholar

[39] Ortiz Bish F, Ruiz Clemente J, Galera Ruiz H, De Mingo Fernández EJ, Muñoz Borge F. [Malignant laryngeal fibrous histiocytoma (MLFH). Report of two unusual cases]. Acta Otorri-nolaringol Esp. 2004 Oct;55(8):390-39410.1016/S0001-6519(04)78541-6Search in Google Scholar

[40] Sanchez-Hernandez Y, Laforenza U, Bonetti E, Fontana J, Dragoni S, Russo M et al. Store operated Ca²⁺ entry is expressed in human endothelial progenitor cells. Stem Cells and Development 2010 Dec;19(12):1967-198110.1089/scd.2010.0047Search in Google Scholar PubMed

[41] Dragoni S, Laforenza U, Bonetti E, Lodola F, Bottino C, Guerra G et al. Canonical Transient Receptor Potential 3 channel triggers VEGF-induced intracellular ca²⁺ oscillations in endothelial progenitor cells isolated from umbilical cord blood. Stem Cells and Development 2013 Oct 1;22(19):2561-258010.1089/scd.2013.0032Search in Google Scholar PubMed

[42] Dragoni S, Laforenza U, Bonetti E, Lodola F, Bottino C, Berra-Romani R et al. Vascular endothelial growth factor stimulates endothelial colony forming cells proliferation and tubulogenesis by inducing oscillations in intracellular Ca²⁺ concentration. Stem Cells. 2011 Nov;29(11):1898-190710.1002/stem.734Search in Google Scholar PubMed

[43] Berra-Romani R, Avelino-Cruz JE, Raqeeb A, Della Corte A, Cinelli M, Montagnani S et al. Ca²⁺-dependent nitric oxide release in the injured endothelium of excised rat aorta: a promising mechanism applying in vascular prosthetic devices in aging patients. BMC Surg 2013 Oct 8;13(Suppl 2):S4010.1186/1471-2482-13-S2-S40Search in Google Scholar PubMed PubMed Central

[44] Berra-Romani R, Raqeeb A, Torres-Jácome J, Guzman-Silva A, Guerra G, Tanzi F et al. The mechanism of injury-induced intracellular calcium concentration oscillations in the endothelium of excised rat aorta. J Vasc Res. 2012;49(1):65-7610.1159/000329618Search in Google Scholar PubMed

[45] Potenza DM, Guerra G, Avanzato D, Poletto V, Pareek S, Guido D et al. Hydrogen sulphide triggers VEGF-induced intracellular Ca²⁺ signals in human endothelial cells but not in their immature progenitors. Cell Calcium. 2014 Sep;56(3):225-23410.1016/j.ceca.2014.07.010Search in Google Scholar PubMed

[46] Dragoni S, Guerra G, Pla Af, Bertoni G, Rappa A, Poletto V et al. A Functional Transient Receptor Potential Vanilloid 4 (Trpv4) Channel Is Expressed In Human Endothelial Progenitor Cells. J Cell Physiol 2015 Jan;230(1):95-10410.1002/jcp.24686Search in Google Scholar PubMed

[47] Moccia F, Guerra G. Ca²⁺ Signalling in Endothelial Progenitor Cells: Friend or Foe? J Cell Physiol. 2016 Feb;231(2):314-32710.1002/jcp.25126Search in Google Scholar PubMed

[48] Zuccolo E, Bottino C, Diofano F, Poletto V, Codazzi AC, Mannarino S et al. Constitutive store-operated Ca²⁺ entry leads to enhanced nitric oxide production and proliferation in infantile hemangioma-derived endothelial colony forming cells. Stem Cells Dev. 2016 Feb 15;25(4):301-31910.1089/scd.2015.0240Search in Google Scholar PubMed

[49] Poletto V, Dragoni S, Lim D, Biggiogera M, Aronica A, Cinelli M et al. Endoplasmic Reticulum Ca²⁺ Handling and Apoptotic Resistance in Tumor-Derived Endothelial Colony Forming Cells. J Cell Biochem. 2016 Feb 24. 10.1002/jcb.25524.[Epub ahead of print]10.1002/jcb.25524Search in Google Scholar PubMed

Received: 2016-1-7

Accepted: 2016-4-20

Published Online: 2016-6-23

Published in Print: 2016-1-1

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.